9 June 2026 - Chiesi Global Rare Diseases today announced that Health Canada has accepted the new drug submission for Filzuvez (birch triterpenes) topical gel for priority review for the proposed indication of the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in patients 6 months of age and older. 

Under Health Canada’s priority review pathway, the new drug submission is subject to an accelerated review timeline of approximately 180 days, in comparison to the traditional 300 day timeline.

Read Chiesi press release